Sparrow Pharmaceuticals
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Sparrow Pharmaceuticals sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).
Sparrow Pharmaceuticals: 6 sponsored US clinical trials, 2 recruiting.
Sparrow Pharmaceuticals sponsors 6 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 4 completed. 0 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Moderate Renal Impairment, with 1 trials.
Upper-quartile sponsor footprint
Sparrow Pharmaceuticals sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
6 total, page 1 of 1
Clofutriben Pharmacokinetics in Patients With Impaired Renal Function
NCT07227922
Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)
NCT07296484
Pharmacokinetic Interaction Trial of Clofutriben With Midazolam and Prednisolone
NCT07226635
SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor
NCT05436639
SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome
NCT05307328
A Study to Assess 11 Beta-hydroxysteroid Dehydrogenase Type 1 Inhibition in Adipose Tissue by SPI-62
NCT05409027
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 3 |
Therapeutic Areas
What is open in the Sparrow Pharmaceuticals pipeline
2 recruiting of 6 indexed (33% open); 4 completed (67%).
Phase mix: 0 late (III/IV) vs 6 early (I/II) (early-phase heavy).
Top condition: Moderate Renal Impairment (1 trial), 3 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Sparrow Pharmaceuticals: open-pipeline peers nationwide
Peers matched on 6 registered trials and 33% open enrollment, not the therapeutic-area sidebar.
Sparrow Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 6 trials (± recruiting share)
- 23andMe · 6 trials · 0% recruiting
- Aardvark Therapeutics · 6 trials · 0% recruiting
- Abbisko Therapeutics Co · 6 trials · 67% recruiting
- AbGenomics B.V Taiwan Branch · 6 trials · 0% recruiting
Sponsors near 33% open enrollment (± trial volume)
- Aadi Bioscience · 33% recruiting · 9 trials
- Aaron Cook · 33% recruiting · 3 trials
- Abivax S.A. · 33% recruiting · 6 trials
- Actuated Medical · 33% recruiting · 3 trials
Related
What to do with this Sparrow Pharmaceuticals page
6 registered trials is a research-attention snapshot, not an endorsement of Sparrow Pharmaceuticals or any single study.
- 2 of Sparrow Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Moderate Renal Impairment is the condition Sparrow Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Moderate Renal Impairment trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Sparrow Pharmaceuticals pipeline card: 6 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.